Posted innews
初级保健中健康老龄化的标准集：新核心结果集(COS)的关键建议
新开发的核心结果集(COS)概述，用于初级保健中的健康老龄化——12个优先结果，旨在标准化健康促进干预措施的评估并提高研究和项目之间的可比性。
Posted inFamily Medicine & Nutrition news Public Health
A Standard Set for Healthy Aging in Primary Care: Key Recommendations from the New Core Outcome Set (COS) Consensus
A concise overview of the newly developed Core Outcome Set for healthy aging in primary care—12 prioritized outcomes to standardize evaluation of health-promotion interventions and improve comparability across studies and programs.
Posted innews Public Health Respiratory
What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
Posted inInfectious Diseases news Public Health
DEN-CORE: An international consensus COMS to standardise dengue clinical trials
An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.
Posted inInfectious Diseases news
Ensitrelvir Matches Ritonavir‑Boosted Nirmatrelvir for Rapid SARS‑CoV‑2 Clearance — PLATCOV Phase 2 Results Support an Alternative Oral Mpro Inhibitor
Phase 2 PLATCOV results show oral ensitrelvir accelerates SARS‑CoV‑2 clearance versus no drug and has antiviral effects close to ritonavir‑boosted nirmatrelvir, supporting further phase 3 evaluation.
Balancing Benefit and Harm: How Long Should Androgen Deprivation Therapy Be Given With Radiotherapy for Localized Prostate Cancer?
An individual-patient data meta-analysis of 10,266 men shows nonlinear oncologic benefit from longer ADT with radiotherapy (diminishing beyond 9–12 months) but increasing other-cause mortality with long-term ADT; optimal duration should be individualized by risk group and competing risks.
Validated IMPACT Tool Enables Risk‑Stratified Outpatient Management of Incidental Meningioma
A large international cohort externally validated the IMPACT clinical tool, demonstrating accurate prediction of incidental meningioma progression and supporting triage to early intervention, serial monitoring, or safe discharge.
Marburg Virus Disease in Rwanda, 2024: Epidemiology, Clinical Management, and Public Health Response
This review synthesizes evidence from Rwanda's 2024 Marburg virus disease outbreak, highlighting epidemiologic characteristics, clinical presentations, investigational therapeutics, and vaccine deployment strategies that contributed to outbreak control and reduced mortality.
Posted inInfectious Diseases news Pediatrics
An 18‑Month VLA15 Booster Elicits Robust Anti‑OspA Responses and Shows Favorable Tolerability Across Ages
An 18‑month booster of the VLA15 Lyme vaccine candidate produced strong anamnestic anti‑OspA IgG responses exceeding primary‑series levels in children, adolescents, and adults, with a tolerability profile similar to primary doses.
Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies
This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies and patient management.
Posted inInfectious Diseases news Public Health
A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda
In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation of the 5×10^10-particle dose.
Posted inInfectious Diseases news
Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection
A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑inferior to 14 days for 90‑day mortality.
Posted inInfectious Diseases Neurology news Public Health
Targeted Vaccination Is Most Efficient but Not Cost‑Effective: National Serosurvey and Modelling of Japanese Encephalitis in Bangladesh
A nationally representative serosurvey and transmission modelling study in Bangladesh estimates low population-level JEV exposure but large numbers of infections annually; spatially targeted vaccination would be most efficient, though not cost-effective under conventional thresholds.
Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
Posted innews
再組合四價流感ワクチン（RIV4）は、9〜17歳の非劣性の免疫原性と許容可能な安全性を示す：第3相免疫ブリッジング試験の結果
第3相免疫ブリッジング試験では、再組合四価インフルエンザワクチン（RIV4）の単回投与が、9〜17歳の青少年において18〜49歳の成人に比べて非劣性のHAI反応を誘導し、同等の安全性プロファイルとより少ない所見反応を示した。
Posted inInfectious Diseases news Pediatrics
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Brand-Specific Influenza Vaccine Effectiveness in Nordic Older Adults: Insights from the 2024-2025 Season Registry-Based Target Trial Emulation
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the clinical impact of high-dose adjuvanted vaccines.
Posted innews Pediatrics Psychiatry Public Health
Peer Self-harm Predicts a Small Increase in Adolescent Risk with a Peak at Age 16: Findings from a Nationwide Finnish Cohort
A Finnish registry cohort (n=913,149) found that exposure to same-grade schoolmates' self-harm modestly increased later self-harm risk (HR 1.05), with the largest effect around age 16 (HR ~1.45), suggesting time-limited social transmission modulated by developmental transitions.
Posted innews Public Health
Wildfire Smoke During Pregnancy Linked to Higher Preterm Birth Risk in the US West: ECHO Cohort Analysis Shows Intensity, Duration, and Timing Matter
A nationwide ECHO analysis found wildfire-specific PM2.5 exposure was associated with increased odds of preterm birth in the US West, with stronger effects for higher concentration, longer smoke waves, and mid-to-late pregnancy exposures.
Posted inClinical Updates Gastroenterology Neurology news
Efficacy and Implementation of a Digital Cognitive Behavioural Self-Management Programme (IBD-BOOST) for Fatigue, Pain, and Faecal Incontinence in Inflammatory Bowel Disease: A Comprehensive Review
This review evaluates the IBD-BOOST digital cognitive behavioural self-management intervention's design, trial outcomes, process evaluation, and clinical implications for managing fatigue, pain, and faecal incontinence in IBD.